Tumor Infiltrating Lymphocytes

Prior treatment with newer-generation therapies appeared associated with significantly lower objective response rates among patients who received tumor-infiltrating lymphocytes for metastatic melanoma, according to study findings.

Moffitt Cancer Center in Tampa has been one of the early leaders in cellular therapies for cancer treatment.

Each 6-month decrease in exposure to immune checkpoint inhibitors nearly doubled the duration of response to therapy with lifileucel among patients with metastatic melanoma, according to long-term results of a phase 2 study.

What if the next paradigm shift in cancer treatment isn’t something new? What if it is something that has been on super-low burn for an entire generation?

More than half of patients with heavily pretreated melanoma responded to therapy with unselected tumor-infiltrating lymphocytes, according to results of a retrospective study.

More than 80% of patients with heavily pretreated metastatic melanoma experienced tumor shrinkage after receiving the adoptive cell therapy lifileucel, according to results of a phase 2 study.

April is Head and Neck Cancer Awareness Month.

The FDA cleared an investigational new drug application for the combination of AFM24 and SNK-01 in patients with solid tumors that express epidermal growth factor receptor, according to a joint press release from each agent’s manufacturer.

Adoptive cell therapies have proved highly effective for patients with certain advanced cancers, particularly melanoma and hematologic malignancies.

The Society for Immunotherapy of Cancer created the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund.